<source: Fox News
Summary
GLP-1 medications, including semaglutide, may offer health benefits beyond weight loss, according to recent research. Studies suggest these drugs could reduce cardiovascular risks, ease joint pain, and improve kidney and liver function. A trial in the New England Journal of Medicine found semaglutide reduced knee osteoarthritis pain and improved physical function. Another study linked the drug to a 24% lower risk of kidney complications in patients with type 2 diabetes. Research also indicates potential benefits for liver health and inflammatory skin conditions. However, the extent to which these effects occur independently of weight loss remains under investigation.
Our Reading
This guidance has been heard before.
GLP-1 drugs show promise for more than just weight loss.
Studies suggest benefits for heart, joints, kidneys, and liver.
Some effects may be linked to weight loss, others not.
Experts say more research is needed to understand the full picture.
Author: Evan Null
GLP-1 Medications and Cardiovascular Benefits
Research suggests that GLP-1 medications, such as semaglutide, may provide cardiovascular benefits beyond weight loss. A major study published in The Lancet found that semaglutide reduced the risk of heart attacks, strokes, and cardiovascular death among people with existing cardiovascular disease and overweight or obesity. The benefits were observed across different body weights and were not fully explained by weight loss.
Joint Pain and Inflammation
GLP-1 medications have been linked to reduced joint pain, although researchers are still investigating how much of the benefit comes from weight loss versus other effects. A clinical trial published in the New England Journal of Medicine found that semaglutide significantly reduced knee osteoarthritis pain and improved physical function among adults with obesity.
Kidney Function and GLP-1 Medications
GLP-1 medications may help protect kidney function through several mechanisms, including improvements in blood sugar, blood pressure, and inflammation. In the landmark FLOW trial, published in the New England Journal of Medicine, semaglutide reduced the risk of major kidney-related complications and cardiovascular death by 24% among patients with type 2 diabetes and chronic kidney disease.
Liver Health and MASH
MASH, or metabolic dysfunction-associated steatohepatitis, is a more severe form of fatty liver disease involving inflammation and liver cell damage. Research suggests GLP-1 medications may help improve liver health, although the extent to which these benefits occur independently of weight loss remains under investigation. A clinical trial published in the New England Journal of Medicine found that semaglutide improved liver tissue findings among patients with MASH, including reductions in inflammation and liver scarring.
Respiratory and Mental Health
Real-world research presented at the European Respiratory Society Congress has linked GLP-1 medications to fewer asthma attacks and COPD flare-ups. Researchers believe the drugs’ potential anti-inflammatory effects may play a role, although additional studies are needed to determine whether the medications directly improve respiratory health. Emerging research also suggests semaglutide may have potential benefits for mental health and addiction, though findings remain preliminary.
